论文部分内容阅读
A major bottleneck in cancer chemotherapy is to achieve specific drug accumulation at the tumor site.This obstacle can be potentially overcome by a targeted delivery approach using nanodelivery systems.To date,several nanotechnology-based therapeutic products have been approved for clinical cancer treatment.However,it has been found that these nanoparticles are predominantly located near the blood vessels and only delivery to the cells on the tumor periiphery takes place,thus offering modest survival benefits [1].